| |
|
|
Daewoong Pharmaceutical (069620) |
|
|
STOCK |
|
|
|
  |
(unit : Won, Share) |
| Fiscal Year End |
07.03 | 08.03 | 09.03 | 09.09 |
| Par Value |
2,500 | 2,500 | 2,500 | 2,500 |
| Yearly Highest Price |
63,500 | 108,500 | 107,000 | 66,800 |
| Yearly Lowest Price |
29,500 | 50,200 | 29,650 | 49,150 |
| Common Shares O/S |
9,878,538 | 9,878,538 | 10,152,219 | 10,427,047 |
| Preferred Shares O/S |
- | - | - | - |
| Market Cap.(100Mn.Won) |
6,272 | 10,718 | 5,329 | 6,016 |
| Dividends (%) |
32.0 | 32.0 | 30.0 | - |
|
 |
(Company/Sector/Market) |
| |
2008.06 | 2009.06 |
| Beta |
0.59 / 0.68 / 1.00 | 0.65 / 0.54 / 1.00 |
| Volatility |
35.72 / 23.43 / 26.01 | 58.81 / 32.47 / 41.28 |
|
 |
(unit : Won) |
| Fiscal Year End |
07.03 | 08.03 | 09.03 | 09.09 |
| Earnings Per Share |
5,294 | 6,277 | 3,444 | 3,728 |
| Sales Per Share |
43,689 | 51,534 | 57,362 | 63,011 |
| Book Value Per Share |
21,014 | 26,317 | 25,923 | 26,541 |
| Cash Flow Per Share |
5,342.01 | 2,810.33 | 3,288.56 | 8,690.86 |
|
 |
(Unit : Times) |
| Fiscal Year End |
07.03 | 08.03 | 09.03 | 09.09 |
| Price / Earnings (H/L) |
11.99/5.57 | 17.29/8.00 | 31.07/8.61 | 17.92/13.18 |
| Price / Sales (H/L) |
1.45/0.68 | 2.11/0.97 | 1.87/0.52 | 1.06/0.78 |
| Price / Book (H/L) |
3.02/1.40 | 4.12/1.91 | 4.13/1.14 | 2.52/1.85 |
| Price / Cash Flow (H/L) |
11.89 / 5.52 | 38.61 / 17.86 | 32.54 / 9.02 | 7.69 / 5.66 |
|
 |
(Unit : 100Mn.Won, %) |
| Fiscal Year End |
06.03 |
07.03 |
08.03 |
09.03 |
| Company |
Sector |
Company |
Sector |
Company |
Sector |
Company |
Sector |
| Invested Capital |
1,759 |
714 |
2,050 |
708 |
2,342 |
942 |
2,976 |
- |
| NOPLAT |
349 |
54 |
446 |
60 |
509 |
71 |
108 |
- |
| Return on Invested Capital |
19 |
7 |
21 |
8 |
21 |
7 |
3 |
- |
| WACC |
6 |
6 |
7 |
6 |
6 |
6 |
6 |
- |
| Economic Value Added |
232.2 |
8.6 |
301.4 |
10.9 |
356.9 |
5.3 |
- 82.7 |
- |
|
 |
(Unit : 100Mn.Won, Times) |
| Fiscal Year End |
2007.03 | 2008.03 | 2009.03 | 2009.09 |
| Enterprise Value(EV) |
6,272.87 | 10,718.21 | 6,000.77 | 6,157.38 |
| EBITDA |
802.18 | 855.31 | 549.16 | 720.32 |
| EBITDA/Sales |
0.20 | 0.18 | 0.10 | 0.12 |
| EBITDA/Financial Exp. |
18.09 | 57.10 | 12.07 | 11.47 |
| EV/EBITDA |
7.82 | 12.53 | 10.93 | 8.55 |
|
|
|
|
